# Supplemental table 2. Cox regression univariate and multivariate analysis including all covariates potentially impacting on progression free survival

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Variable** | **Univariate analysis** | | | | **Multivariate analysis** | | | |
| **HR** | **95% CI** | | **p** | **HR** | **95% CI** | | **p** |
| *EGFR* T790M positive status | 0.475 | 0.318 | 0.708 | **<0.001** | 0.503 | 0.329 | 0.768 | **0.002** |
| *EGFR* exon 19 deletion vs other mutations | 0.873 | 0.597 | 1.276 | 0.483 |  |  |  |  |
| Stage at diagnosis (IV vs IIIB/IIIC) | 0.915 | 0.474 | 1.764 | 0.790 |  |  |  |  |
| Baseline liver metastases | 1.049 | 0.701 | 1.570 | 0.814 |  |  |  |  |
| Smoking | 1.076 | 0.728 | 1.590 | 0.712 |  |  |  |  |
| Adenocarcinoma histology | 1.088 | 0.443 | 2.673 | 0.853 |  |  |  |  |
| Baseline bone metastases | 1.150 | 0.782 | 1.692 | 0.477 |  |  |  |  |
| Median age at diagnosis (≥65 years vs <65 years) | 1.157 | 0.793 | 1.688 | 0.447 |  |  |  |  |
| Bone metastases at diagnosis | 1.239 | 0.845 | 1.816 | 0.271 |  |  |  |  |
| Charlson (>6 vs 6) | 1.239 | 0.810 | 1.895 | 0.321 |  |  |  |  |
| Previous treatment with afatinib | 1.279 | 0.864 | 1.892 | 0.217 |  |  |  |  |
| Male sex | 1.306 | 0.890 | 1.916 | 0.171 |  |  |  |  |
| Liver metastases at diagnosis | 1.309 | 0.797 | 2.151 | 0.286 |  |  |  |  |
| ECOG PS at diagnosis (2 vs 0-1) | 1.345 | 0.651 | 2.776 | 0.423 |  |  |  |  |
| Brain metastases at diagnosis | 1.387 | 0.859 | 2.239 | 0.179 |  |  |  |  |
| Baseline brain metastases | 1.638 | 1.047 | 2.562 | **0.031** | 1.824 | 1.143 | 2.912 | **0.012** |
| Previous TKI best response (SD/PD vs CR/PR) | 1.680 | 1.139 | 2.481 | **0.009** | 1.045 | 0.668 | 1.634 | 0.847 |
| Best response to treatment (SD/PD vs CR/PR) | 2.986 | 2.030 | 4.394 | **<0.001** | 2.893 | 1.847 | 4.533 | **<0.001** |

Significant values are highlighted in bold. HR, hazard ratio, 95%CI, 95% confidence interval, CR, complete response, PR, partial response, SD, stable disease, PD, progressive disease, TKI, tyrosine kinase inhibitor, ECOG PS, Eastern Cooperative Oncology Group Performance Status